|Home | About | Journals | Submit | Contact Us | Français|
Biomedical Research Centres (BRCs) are partnerships between healthcare organisations and universities in England. Their mission is to generate novel treatments, technologies, diagnostics and other interventions that increase the country’s international competitiveness, to rapidly translate these innovations into benefits for patients, and to improve efficiency and reduce waste in healthcare. As NIHR Oxford BRC (Oxford BRC) enters its third 5-year funding period, we seek to (1) apply the evidence base on how best to support the various partnerships in this large, multi-stakeholder research system and (2) research how these partnerships play out in a new, ambitious programme of translational research.
Organisational case study, informed by the principles of action research. A cross-cutting theme, ‘Partnerships for Health, Wealth and Innovation’ has been established with multiple sub-themes (drug development, device development, business support and commercialisation, research methodology and statistics, health economics, bioethics, patient and public involvement and engagement, knowledge translation, and education and training) to support individual BRC research themes and generate cross-theme learning.
The ‘Partnerships’ theme will support the BRC’s goals by facilitating six types of partnership (with patients and citizens, clinical services, industry, across the NIHR infrastructure, across academic disciplines, and with policymakers and payers) through a range of engagement platforms and activities. We will develop a longitudinal progress narrative centred around exemplar case studies, and apply theoretical models from innovation studies (Triple Helix), sociology of science (Mode 2 knowledge production) and business studies (Value Co-creation). Data sources will be the empirical research studies within individual BRC research themes (who will apply separately for NHS ethics approval), plus documentary analysis and interviews and ethnography with research stakeholders. This study has received ethics clearance through the University of Oxford Central University Research Ethics Committee.
We anticipate that this work will add significant value to Oxford BRC. We predict accelerated knowledge translation; closer alignment of the innovation process with patient priorities and the principles of responsible, ethical research; reduction in research waste; new knowledge about the governance and activities of multi-stakeholder research partnerships and the contexts in which they operate; and capacity-building that reflects the future needs of a rapidly-evolving health research system.
Cross-sector research partnerships are an important component of the contemporary research landscape. The National Institute for Health Research (NIHR), for example, invests over £1 billion per year supporting partnerships between National Health Service (NHS) organisations and universities in England. Most notably, these include NIHR Biomedical Research Centres (BRCs) and NIHR Collaborations for Leadership in Applied Health Research and Care (CLAHRCs) [1–4]. The United Kingdom Department of Health also invests efforts and resources in wider multi-stakeholder partnerships, including Academic Health Science Centres (AHSCs) and Academic Health Science Networks [5–7], described as the NHS’s “gateway to the life sciences industry” . All these structures encourage strong links with industry and high levels of patient and public involvement and engagement.
The goal of NIHR BRCs is to accelerate both ‘T1’ translational research (from the laboratory bench to clinical trials) and ‘T2’ translational research (from clinical trials to implementation in clinical practice and policy) [2, 9]. The first wave of these BRCs was established in 2007; as of April 2017, there are 20 such centres nationally. As stated by the NIHR, their aims are to  drive innovation in the prevention, diagnosis and treatment of ill-health, translate advances in biomedical research into benefits for patients, and help the NHS contribute to the nation’s international competitiveness.
Whilst NIHR BRCs are specific to the United Kingdom, the idea for cross-sector research partnerships aimed at rapidly promoting and translating life sciences and technology research into benefits for patients originated in the United States of America . These networked structures are now a global phenomenon [11, 12], intended to generate synergies that drive innovation and accelerate the translational research pathway .
There is evidence to suggest that NIHR BRCs, including one in Oxford, have had some positive impacts on resource targeting, management and governance in translational research for patient benefit at the interface between NHS organisations, universities and industry, but there is also some evidence of negative impacts and a number of as yet unexploited opportunities to maximise the value of biomedical research [13–15]. Research on similar cross-sector translational research partnerships in other countries suggests that they sometimes, but not always, achieve their goals [16–18]. Some authors have argued that cross-sector partnerships in rapidly-developing, high-technology fields may generate substantial research waste as patients’ needs and priorities are overlooked in favour of the relentless pursuit of innovation and commercial influences that conflict with the pursuit of the public good [19–21]. Others have taken the opposite view and argued that there is evidence of significant societal impact and economies of scale from such partnerships . A recent review that asked whether concentrating research funding into a small number of very large research centres (as in BRCs) was likely to produce economies or diseconomies of scale concluded that there were examples of both in the literature .
Underpinning the policy of ‘innovation, health and wealth’ is the implicit assumption that pursuit of the first of these goals (innovation) through what has been termed the ‘managed network’ approach  will – if strategic drivers are appropriately aligned – generate the second two [25–27]. The rationale for this policy is that, in order to keep pace with rising expectations and growing demand, especially when innovation generates interventions that are both effective and costly, the health sector needs to become more efficient, embrace innovations that are both effective and cost-effective, and generate additional income. Potentially, this can be achieved through a thriving regional innovation system that accelerates economic growth and wealth creation while at the same time generating worthwhile innovations for use in the NHS.
From its inception, the NIHR has strongly supported patient and public involvement and engagement (PPI/E), the former being defined as involvement of patients in the design, delivery and dissemination of research, and the latter as outreach from research scientists to communities and citizens . The many and varied PPI/E activities by NIHR BRCs appear to align respectably with calls for the ‘democratisation’ of science [29, 30] and have produced some (albeit relatively weak) evidence of societal impact . However, there is also evidence that the underpinning values driving high-technology biomedical research may sometimes be at odds with those of patients and citizens [32–34], and that, whilst BRC-funded researchers have been content for patients and the public to ‘tinker at the edges’ with science through consultation and outreach, some remain opposed to genuinely democratic partnerships in which citizens and scientists collaboratively set a research agenda and jointly oversee its delivery .
More broadly, BRCs lack an explicit link to the wider policy context for their work. NIHR BRCs are depicted as facilitating a pathway from basic bench science through to clinical practice, but – surprisingly – the surrounding policy context does not figure in core documents describing their scope and purpose [3, 9, 25]. Yet, this policy context heavily conditions that process of translation at every stage. It determines, for example, what other funds are available, what rules govern different stages of research such as clinical trials, what intellectual property rules apply to products versus service changes, and how different innovations relate to the financing and organisation of the NHS .
In sum, multi-stakeholder research partnerships, particularly in high-technology biomedical research with significant commercialisation potential, appear to be characterised by inherent complexity, multiple drivers, conflicting values and contested metrics of success. The potential synergies associated with these new organisational forms are considerable, but they are not guaranteed. Whilst the goals of ‘innovation’, ‘health’ and ‘wealth’ have been rhetorically aligned in policy documents and support a plausible narrative, they do not always march in step. Work must be done to maximise synergies, minimise waste and ensure responsible research and innovation.
Accordingly, as the NIHR Oxford BRC enters its third 5-year funding period (2017–2022), we present this study protocol for a programme of research seeking to (1) apply the existing evidence base on how best to support the various partnerships in this large, knowledge-based, multi-stakeholder research system; and (2) research how these partnerships play out in a new and ambitious programme of translational research.
Developing, pre-registering and publishing a study protocol for this novel programme of research spanning the entire NIHR Oxford BRC and other cross-sector research partnerships in the Oxford region is an important step towards maximising the value of the NIHR’s investment in research. It has the potential to strengthen the scientific rigour of the proposed research, optimise the efficiency of the research process, and improve the reproducibility of results, for the reasons stated below.
First, carefully developing and scrutinising research questions – both by the ‘Partnerships’ core research team and through independent oversight and external peer review – at the research design stage can simplify data collection, make data analysis more rigorous, and strengthen the quality of reporting . We have developed this study protocol in collaboration with all researchers involved in the ‘Partnerships’ cross-cutting theme and have incorporated critical input from the leaders of other BRC themes and an external advisory group. To strengthen the quality of reporting and the potential for theorising, we will use published methodology for ‘n of 1’ case study research [37–39], adapting as appropriate to the unique nature of the case(s) under scrutiny.
Second, transparency can improve the quality of research and avoid duplication of effort by different researchers conducting similar research . While registering experimental clinical studies on websites such as clinicaltrials.gov is now standard practice, this is not the case for qualitative case studies. To increase transparency and discoverability of our research, we have created a dedicated project page on a social networking site for scientists (see Dissemination section below). Moreover, to ensure unrestricted access to our research, we commit to publishing in open access journals.
Finally, publishing a study protocol helps mitigate publication bias, which (when it occurs) limits the available evidence base and wastes time and resources on repeating studies that have been conducted elsewhere. Large-scale organisational case studies of knowledge translation are rarely published unless they describe positive findings, which suggests that this study design may currently be particularly open to publication bias . By publishing our study protocol, we make a public commitment to publishing all of our research, including both positive, negative and ambiguous findings.
This study takes place in the Oxford region of the United Kingdom, which in addition to the NIHR Oxford BRC includes a comprehensive range of other NIHR research infrastructure within the AHSC in Oxford and the larger Academic Health Sciences Network region covering a population of 3.3 million across the Thames Valley and Milton Keynes (Fig. 1). The region is currently home to one of the world’s most significant biotechnology clusters and one of the United Kingdom’s leading NHS–university partnerships as measured by formal metrics of research volume, collaboration with industry, intellectual property and spin-out companies [42–45]. The region has a highly skilled labour force, especially in Oxfordshire, and over 46,000 jobs in high-tech firms across a range of technologies . However, there are also pockets of deprivation and unemployment along with significant housing shortages and unmet health needs. A recent report on health inequalities in Oxfordshire highlighted the need for innovation, wealth creation and poverty reduction as part of a cross-sector approach to reducing inequalities .
The NIHR Oxford BRC is based on partnerships between the Oxford University Hospitals NHS Foundation Trust and the University of Oxford, and externally with industry and other NIHR infrastructure (http://oxfordbrc.nihr.ac.uk). It was first established in 2007 with a NIHR award of £57 million over 5 years; renewed in 2012, with a NIHR award of £96 million for a further 5 years; and awarded £114 million of NIHR funding for 2017–2022. This funding buys out time of front-line clinicians and university academics and provides resources to conduct translational research across a range of disease-related and cross-cutting research themes. The NIHR Oxford BRC also played a seminal role in the development of a successful bid for a second BRC in Oxford, focusing on mental health and linked to the community-based Oxford Health NHS Foundation Trust. The NIHR Oxford Health BRC was established with a NIHR award of £13 million for 2017–2022. The two BRCs work closely together as part of Oxford AHSC in areas such as big data, personalised medicine, and multiple long-term conditions and dementia.
As of April 2017, the NIHR Oxford BRC has 16 disease-related research themes (e.g. diabetes, vaccines) organised into four clusters (Fig. 2). Each seeks to bring together scientific excellence, expertise and engagement platforms (see below for definition), thereby achieving focus and critical mass in a specific area. Grouping themes into clusters (e.g. chronic diseases) is a new approach from 2017, intended to amplify this critical mass and drive cross-disciplinary capabilities that address major healthcare opportunities and challenges such as prevention and early diagnosis. Also newly introduced in 2017 are formal cross-cutting themes (shown as the inner circular segments in Fig. 2) that provide technological platforms and generic capabilities (e.g. informatics, diagnostics) to support the disease-related research themes.
An important additional innovation for the NIHR Oxford BRC in 2017 has been the establishment of a large and integrative cross-cutting theme – ‘Partnerships for Health, Wealth and Innovation’, with multiple sub-themes (listed below under ‘Programme management and governance’). ‘Partnerships’, shown as the innermost circle in Fig. 2, aims to provide co-ordinated and targeted support to individual BRC themes and generate cross-theme learning through research on research. Below, we describe the aims, objectives, methodology, dissemination plan and intended outcomes of the Partnerships theme.
The aim of the NIHR Oxford BRC 2017–2022 is to deliver on the NIHR’s stated objectives for BRCs (described in ‘Background’ above) through enhanced cross-disciplinary and inter-sectoral partnerships designed to produce synergies that can address major healthcare challenges at scale.
The strategic objectives of the ‘Partnerships’ theme are (1) to support the aims of the NIHR Oxford BRC through a set of co-ordinated cross-cutting platforms and activities designed to strengthen six types of partnership (Fig. 3) and (2) to generate new knowledge about the governance and activities of high-technology, multi-stakeholder health research partnerships.
Figure 3 shows the key partnerships we seek to build. We expand on these below.
NIHR Oxford BRC seeks to ensure that its research addresses patients’ priorities and is a good use of public funds. The ‘Partnerships’ external advisory group (see below) has been established with a lay chair and strong representation from patients and citizens. We will support all BRC research themes to value the patient’s perspective; integrate patient involvement and public engagement into all aspects of their research activity; measure their success using metrics that allow comparison over time and across themes; and improve their performance year on year.
Traditionally, there has been an unacceptable delay between doing academic research and implementing research findings in a way that benefits patients. We know that, when research ideas come directly from front-line clinical practice and scientists work closely with clinicians to design and undertake research studies, this ‘bench to bedside translational gap’ can be bridged more effectively . The ‘Partnerships’ theme will include a work stream on knowledge translation and implementation science (see these introductory papers for definitions and rationale [48, 49]) with a view to getting research discoveries rapidly into practice. Research links with clinical services that aim to introduce new drugs, devices or service models raise implications for local commissioning and funding models (see ‘Policymakers and payers’ below).
The biotechnology, pharmaceuticals, medical devices and software industries are important contributors to both healthcare and national economic growth [34, 50]. We will help to link the BRC to industry partners with a view to building networks and collaborations that enable co-production of knowledge, leverage additional funding for research, enrich the training of early career researchers (e.g. through reciprocal placements) and increase economic and societal impact by helping to turn research ideas into marketable real-world innovations. We will also explore ways of making conflicts of interest explicit and ensuring that value for private-sector partners is not achieved at the expense of the public good.
NIHR-funded research infrastructure in Oxford includes two BRCs, a CLAHRC, a Clinical Research Facility, a Clinical Research Network, a Health Protection Research Unit, and a Diagnostic Evidence Co-operative, which is currently being transformed into a MedTech and In Vitro Diagnostic Co-operative. This infrastructure embraces multiple research themes, theme clusters and cross-cutting themes, and covers all stages in the health research pathway from the basic sciences to implementation and evaluation of new service models. In large and complex research structures such as this, there is a danger that individual research teams could become isolated into silos and lose the sense of shared endeavour. By drawing out common challenges and emerging patterns across the Oxford BRC and beyond to Oxfordshire’s wider research infrastructure, we will help to engender a sense of coherence and generate knowledge that supports and improves the effectiveness of the NIHR infrastructure as a whole.
We will encourage interdisciplinary collaborations within the University of Oxford, with other higher education institutions within and beyond the United Kingdom, and with scholars who work outside the higher education sector. The BRC provides exciting opportunities for interdisciplinary collaborations between biomedical scientists and academics from complementary fields, including statistics, economics, computer science, business studies, and the humanities and social sciences. Interdisciplinary research enables large and ambitious projects (for example, multi-centre clinical trials or big data analytics). It also allows us to do research on research by asking over-arching questions about how to optimise the research process, improve the governance and ethics of research, train and support early career researchers, work with industry and government, and implement the findings of research in clinical practice.
Biomedical research at Oxford seeks to improve the effectiveness and efficiency of local health services through evidence-based healthcare policymaking and commissioning and also to provide knowledge that can inform national and international-level decisions relating to research policy in the life sciences, technology and health sciences. The role of payers in bridging the translational gap between research and clinical services is critical, especially in times of financial austerity, but to date has been relatively under-researched and mostly limited to specific studies of the commissioning process. This study will include an analysis of how payers (national and local, public and private) fit with the wider ecosystem of healthcare and health research, and either facilitate or inhibit the translation of innovations into clinical practice. Our work also has implications (for example) for the regulatory processes for drugs and medical devices and the conduct of clinical trials. Therefore, we will develop Oxford BRC’s existing links to local and national policymakers and to international bodies in science and healthcare.
For more specific research questions to be addressed by defined work packages within the ‘Partnerships’ theme, see Table 1.
The study design is an organisational case study [38, 39], informed by the principles of action research . We begin from the position that the knowledge base will benefit most not from a technocratic, ‘logic model’ approach to the study of innovation and research impact, but from a systematic, maximum-variety sample of richly-described and theorised case studies. As Bent Flyvbjerg has observed in his classic paper Five Misunderstandings about Case Study Research:
“[A] scientific discipline without a large number of thoroughly executed case studies is a discipline without systematic production of exemplars, and … a discipline without exemplars is an ineffective one. Social science may be strengthened by the execution of more good case studies” .
Given its strong track record of success against conventionally accepted metrics, NIHR Oxford BRC represents a crucial case study of a regional innovation system because it is strategically positioned to develop and test a new model of economic growth and societal impact based on high-value adding health research and the biotechnology industry. The term ‘crucial case study’ comes from the notion that, if a proposition (such as ‘synergies will result from working in cross-sector partnerships’) fails when conditions are highly favourable, then it is unlikely to work in less favourable conditions .
The ‘Partnerships’ research theme is led by TG and includes a core research team (NF, PO, SS, PK, AR) whose roles include overall co-ordination and PPI/E as well as ‘research on research’. In addition to, and with a view to supporting, the main BRC steering group, a separate advisory group for the ‘Partnerships’ theme has been established, with reciprocal cross-representation. The former meets 6–8 times a year and the latter 2–3 times a year.
The ‘Partnerships’ theme has a number of sub-themes that are operationally distinct (e.g. each has a designated lead and budget), but which will work collaboratively and flexibly to develop interdisciplinary case studies centred around specific research questions (Table 1). Sub-themes include drug development, medical device development, business support and commercialisation, research methodology and statistics, health economics, bioethics, PPI/E, knowledge translation, and education and training. Sub-theme leads will meet together trimonthly; alternate sub-theme leads meetings will be oriented to producing a formal report for the external advisory group.
A wide range of external stakeholders and independent members will represent the various partnerships shown in Fig. 3 on the ‘Partnerships’ external advisory group, which will have an independent lay chair. This group will scrutinise research questions and provide critical feedback on an ongoing narrative of progress centred around exemplar interdisciplinary case studies and including both qualitative and quantitative data. Members of the external advisory group will also provide important connections to stakeholder organisations, including leveraging opportunities to increase value for money of the NIHR’s investment.
Most importantly, the external advisory group will seek to establish social accountability of the ‘Partnerships’ cross-cutting theme to patients and the public in the spirit of the ‘democratization’ of science [29, 30]. Whereas NHS-university partnerships in England are characterised by bifurcating hierarchical, legal, professional and political accountabilities to various government departments, public agencies and professional organisations, the structures and processes for establishing social accountability have yet to be formally established .
The ‘Partnerships’ external advisory group will address the desirability and priority of current and proposed research topics and approaches, with particular emphasis on improving patient care, educating and training tomorrow’s clinician and scientist leaders, reducing research waste and advancing translational research. An important aspect of the external advisory group’s work will be to deliberate on research priorities, such as the trade-off between research that leads to short-term patient benefits locally versus research that is more oriented to filling national or global knowledge gaps and/or to the medium or long term.
We will draw eclectically and critically on three closely related theoretical frameworks, which were respectively developed in innovation studies (the Triple Helix), the sociology of knowledge (Mode 2 knowledge production), and business and management (value co-creation). All have strengths and limitations and will need to be adapted as we apply them to the emerging case study. We describe these in turn.
In their Triple Helix model, Etzkowitz et al. [53, 54] highlight how universities, industry and government, once separate and independently evolving entities, are increasingly interdependent and co-evolving, with each sector taking on elements of the others’ traditional roles (for example, universities develop the capacity to interact with industry and commercialise discoveries, industry develops the capacity to undertake research, and government provides ‘public venture capital’), while also retaining a core identity as, respectively, academic, commercial and state institutions.
Central to the Triple Helix model is the creation and support of three ‘spaces’ :
A key component of the Triple Helix model is the notion of ‘new organisational actors’ – organisational formats that straddle traditional university–industry–state boundaries – such as incubators, science parks and new models of venture capital (including, for example, social enterprise or patient charities) . Indeed, the study of the Triple Helix may focus fruitfully on the emergence and behaviour of these new organisational actors (for example, the entrepreneurial university still trains individuals in classrooms, but it also has a more contemporary role of training organisations in incubators).
Etzkowitz and Leydesdorff  emphasise that the Triple Helix rests on an active, questioning civil society in which public debate over values and scientific priorities, and bottom-up initiatives of various kinds, feed into the emergent decisions and actions of macro-level stakeholders. The exchange of ideas, knowledge and perspectives is facilitated by free movement of individuals between the different strands of the helix, for example, through placements for students in industry or policy and, conversely, university secondments and honorary lectureships for people from industry, government or the civil service. Such a model depends on reflexivity, that is, ongoing appraisal by the university of its evolving relationships with industry, government and civil society.
The Triple Helix metaphor is presented positively by its protagonists as enhancing the potential for innovation and economic growth in a knowledge-based society. It is worth noting that critics of the Triple Helix have warned of the danger of ‘irresponsible innovation’ that may result from a combination of strong commercial drivers, technology push, policy pull, marginalisation of ethical principles, lack of precautionary measures and tokenistic rather than democratic input from patients and citizens [56–59]. Perhaps another way of expressing this criticism is that civil society was included as part of the context for the Triple Helix but not as an equal and integral strand within it.
Our second theoretical influence is Gibbons et al.’s  Mode 2 Knowledge Production. In contrast to the traditional Mode 1 model of university research (produced by discipline-specific groups in ivory towers and then translated, disseminated and applied outside the academic sector), Mode 2 knowledge is “socially distributed, application-oriented, trans-disciplinary and subject to multiple accountabilities” . As summarised previously:
“Such knowledge is generated partly or wholly outside the university in a heterogeneous transaction space embracing university, state, economy, culture, and the wider public sphere. In this space, problems are identified, questions debated, methodologies developed, and outcomes disseminated. There are many players, many experts (of different kinds), and an evolving collective view (though rarely a consensus) on what the questions and challenges are.” 
Unlike the producer-consumer or contractor-commissioner relationship between researchers and research end-users in traditional ‘Mode 1’ scientific research, relationships between researchers and users in Mode 2 are (ideally) democratic and collaborative, and seek to generate knowledge that is both socially and scientifically robust. However, such an approach constitutes a significant challenge to the norms of academic science, as set out back in 1938 by Merton , which include disinterestedness, objectivity and organised scepticism. The philosophical tension between a ‘disinterested’ science conducted by academics isolated from society and a ‘socially engaged’ science conducted in partnership – or at least in dialogue – with civil society is beyond the scope of this paper, but one which we will seek to explore as this programme of work unfolds.
As with the Triple Helix model, the Mode 2 model has been criticised for taking a politically naïve perspective and overlooking the power of vested interests to distort the research agenda [64, 65]. Indeed, critical academics have proposed adding Mode 0 – “knowledge production based on relations of power and patronage” –  to Gibbons et al.’s  original taxonomy. The question of how best to harness the co-creative potential of Mode 2 without overly distorting the research agenda with commercial and other powerful interests is one of the leading challenges of contemporary health systems research.
The third theoretical framework on which we seek to draw is an adaptation of Ramaswamy et al.’s [67, 68] Value Co-creation model – originally developed for the commercial sector as a business strategy for engaging multiple stakeholders to devise products and services to increase their value for everyone. We have adapted the Value Co-creation model to fit a setting in which the main partners are public sector health and education institutions (Fig. 4).
Ramaswamy and Ozcan  offer four key principles for co-creation of value across sectors:
Central to the model are platforms (of various kinds, formal and informal) for bringing stakeholders together. The co-creation process is supported through two key activities :
As Fig. 4 illustrates, capacity-building occurs both through individual training and development and through the enterprise process itself. Individuals circulate within and between their various communities of practice – business, professional, natural (e.g. geographical) and civic – thus sharing experiences and perspectives. Individuals and groups value different things; communication and dialogue, including but not limited to the formal governance processes of the programme(s), ensure that each stakeholder gets something of what they value and comes to understand and contribute to what others value.
Although the Value Co-creation model originated in business studies, the theoretical ideas of co-creation can be applied to the co-creation of knowledge within the Triple Helix of university–industry–government relations resting on an active civil society . To our knowledge, there has been only one published application of value co-creation in a healthcare setting (in Australia) .
One approach that could potentially bring all three of these perspectives together is what Carayannis et al.  have called “Mode 3 knowledge production in a quadruple helix innovation system”. This framework adds a fourth strand – civil society – to the triple helix and also extends the work of Gibbons et al.  to address the management of power differentials and conflicts of interest and also consider how knowledge production may occur simultaneously across Modes 1 and 2 through what Carayannis and Campbell  call the ‘co-evolution’ of different knowledge and innovation modes. Such an approach emphasises the value of clusters and networks that often stand in ‘co-opetition’ (, p. 41), involving a careful balancing of both cooperation and competition. This hybrid approach will be explored further, with pilot data, in a separate publication.
An engagement platform has been defined by Ramaswamy and Ozcan as “an assemblage of persons, processes, interfaces, and artifacts, whose engagement design affords environments of interactions that intensify agential actions in value creation” (, p. 34).
As Fig. 4 shows, the co-creation of value depends on such platforms, which serve to bring together stakeholders from different sectors and perspectives. Engagement platforms are many and varied; they include formal governance structures, physical spaces, informal networking events and virtual interaction spaces. Examples of engagement platforms (both formal and informal) that are already in place for the Oxford BRC include (1) the inter-sectoral Strategic Partnership Board, which has a Joint Executive Group and specialist committees. These provide governance structures for the oversight of all the aspects of joint working arrangements between the Oxford University Hospitals NHS Foundation Trust and the University of Oxford in accordance with their Joint Working Agreement (Fig. 2). (2) The Oxford Academic Health Science Centre and Network, which are wider partnerships that consolidate interactions between Oxford’s universities, hospitals and industry at the local and regional levels, respectively (Fig. 1). (3) The Oxford Structural Genomics Consortium, which is a university-led, externally facing basic science research group with strong links to major pharmaceutical companies, biotechnology companies, clinical research organisations, and venture capital and patient charities. A major work stream in the ‘Partnerships’ BRC theme seeks to grow the Consortium’s industrial network and build relations with patient organisations and charities to catalyse discovery of new drug targets and inform clinical studies in ways that are patient relevant. (4) The ‘Partnerships’ external advisory group described above brings patient and lay representatives together with BRC theme leads, industry, external academics and stakeholders from the local health economy. (5) The Oxford University Clinical Academic Graduate School (OUCAGS) is a partnership between the University of Oxford and Health Education Thames Valley, which aims to support postgraduate academic education and career development for medical and non-medical staff. Via its website (www.oucags.ox.ac.uk), a regular email newsletter, a range of training courses and regular face-to-face events, it brings doctoral students and early career researchers together and links them with resources and opportunities. (6) The Oxford-BRC-Partnerships Jiscmail list is an academically run list server open to anyone working in or with the Oxford BRC, including patients and the public involved in PPI/E activities. It provides an informal platform for asynchronous email communication, interdisciplinary discussion and resource sharing on the key domains supported by the ‘Partnerships’ theme (drug and device development, industry relations and commercialisation, knowledge translation, patient and public involvement and engagement, ethics, and education and training). (7) Social media presence for the NIHR Oxford BRC includes a Twitter feed and Facebook account (@OxfordBRC). The ‘Partnerships’ theme has a dedicated ResearchGate site for publications and updates and an active Twitter feed (see ‘Planned dissemination and outputs’ below for details of these). Importantly, these social media outlets also serve as a mechanism for inviting feedback and external peer review (both academic and lay) on emerging activity.
The above list is not exhaustive. As the work of the NIHR Oxford BRC unfolds, we anticipate that the number and nature of engagement platforms will change organically. We will capture the emergence, development and attrition of key engagement platforms using ethnographic and narrative methods. Plans include the development of a single point-of-contact for BRC researchers to log help requests from the ‘Partnerships’ sub-themes (Table 1) and a series of face-to-face networking and resource-sharing events.
The ‘Partnerships’ theme will include a number of specific sub-themes (listed above and in Table 1), which will provide a wide variety of different kinds of support and co-ordination. Each sub-theme will select specific case studies from the NIHR Oxford BRC research themes and clusters, to which they will provide both longitudinal support and help with evaluation.
We will ensure that cases are selected to ensure maximum variety in size, structure, duration, academic discipline(s), clinical field, nature of support requested and success metrics, and that all cases have potential to contribute data to address the research questions listed above. The number of case studies will be limited by the need to provide rich description and detailed theoretical analysis (in other words, this will be a ‘small-n’ sample designed for illuminative insights and theoretical generalisability, not one designed to generate statistically representative data).
The study will use a variety of qualitative and quantitative data, including the empirical studies within individual BRC research themes, narrative accounts from stakeholder interviews, ethnographic field notes, documents, and quantitative indicators and metrics of success. Data analysis and synthesis will be informed by the theoretical frameworks outlined above, and also by the objectives of action research, namely (1) informing real-time action and system change through ongoing, formative feedback, and (2) making a generalisable contribution to the knowledge base ; ‘generalisable’ indicates the naturalistic generalisation that is made possible through in-depth case study. In this regard, the design draws on Weick’s work on the ‘generative properties of richness’ (thick description, reflexive theorising, and ‘conceptual slack’ – openness to the many new explanations that emerge when contextual detail is added to an account) in an organisational case study .
Table 1 provides an overview of data structure and analysis plan for specific research questions.
In keeping with the principles of action research and Mode 2 knowledge production, we will engage from the outset with the intended end users of our research. This will maximise the value of our research by increasing its usability and impact while reducing the need for a separate dissemination phase. Specifically, dissemination within the NIHR Oxford BRC and the broader Oxford regional innovation system will occur to a large extent through the researchers’ continuous engagement with the local and regional stakeholders and their active involvement in the co-creation of knowledge.
Dissemination beyond the Oxford regional innovation system will occur through the professional networks of the research team and the ‘Partnerships’ external advisory group, as well as through collaborations, conferences, and publications in (open-access) academic and trade journals. Patients and the public will be able to access the latest research news and multimedia from our cross-cutting theme on the dedicated webpage of the NIHR Oxford BRC (https://oxfordbrc.nihr.ac.uk/research-themes-overview/partnerships-for-health-wealth-and-innovation/). We will also use social networking and social media to increase transparency and broaden outreach. We will post regular updates on our progress and deposit our research outputs on a social networking site for scientists (https://www.researchgate.net/project/Oxford-BRC-Partnerships-for-Health-Wealth-and-Innovation). The ‘Partnerships’ theme leader (TG) is an active contributor to the social media site Twitter (@trishgreenhalgh) and will use it to reach out to global audiences in real time.
In terms of outputs, our short-term goal is to bring together university, industry and NHS partners in strategically targeted projects focused on supporting innovation and escalating promising discoveries. We will develop and strengthen links with clinical trials units and theme-specific projects to ensure that researchers receive methodological support at design stage. We will build relationships with patient/citizen groups, NHS services, industry, policymakers and payers, and undertake needs assessment for researcher training.
In the medium term, our goal is to develop a set of infrastructural capabilities to support more effective partnership dynamics; faster ‘T1’ translation of discovery science into clinical trials and observational studies; larger and more strategic collaborations with industry, the NHS and patients/citizens; research studies that meet the highest standards for methodology and value-for-money; ethical research that is valued by users; high levels of engagement with and from citizens, the local health economy, payers and national policymakers; faster ‘T2’ translation of research findings into clinical practice; research on research that feeds back into formative learning across the NIHR Oxford BRC and the wider NIHR infrastructure; and comprehensive and flexible training and career development for early-career researchers.
In the longer term, we anticipate that our work will add significant value to the NIHR Oxford BRC by unpicking the complexity of multi-stakeholder research partnerships and providing generalisable insights on how to optimise it. We predict accelerated T1 and T2 knowledge translation; closer alignment of the innovation process with patient/citizen priorities and the principles of responsible, ethical research; reduction in research waste; new knowledge about the governance and activities of multi-stakeholder research partnerships and the contexts in which they operate; and capacity-building that reflects the future needs of a rapidly-evolving health research system.
This study protocol has described the rationale and methodology for a novel approach to building and strengthening the various partnerships in the NIHR Oxford BRC and beyond as it embarks on its third 5-year period of NIHR funding from 2017 to 2022. We have presented our BRC as a crucial case study – a setting in which many of the preconditions for success are already in place, hence a good place to test a new approach for enhancing that success. We have introduced three linked theoretical perspectives (Triple Helix, Mode 2 Knowledge Production and Value Co-creation) relevant to the operation of large, multi-stakeholder health research partnerships. We have described the structure and governance of a new ‘Partnerships for Health, Wealth and Innovation’ cross-cutting theme, and, within that theme, we have outlined our plans to support and evaluate a maximum variety sample of cases in different aspects of partnership working. Finally, we have emphasised the importance of creating an ongoing narrative of progress to aid collective sense-making and maintain an over-arching (and evolving) vision.
Previous sociological studies of multi-stakeholder research partnerships have shown that they are inevitably characterised by structural complexity, competing interests, ambiguous loyalties and colliding institutional logics [64, 65, 72, 73]. Synergy may increase as co-governing partners work together, leading to convergence of perspectives by progressive alignment of purpose, values and goals, and growth of mutual understanding and respect. However, this is by no means inevitable; others have used the term ‘collaborative entanglement’ to depict an ongoing instability of the system that will never attain an easy synergy . In some cases, organisations traditionally thought of as odd bedfellows join forces at an early stage to generate a grant application that is “draped in the formal collaborative language and procedures prescribed by funding agency protocols”, but in reality they continue to “view each other pragmatically as consultants, clients or even competitors, rather than partners” .
Multi-stakeholder health research partnerships have been widely studied using ethnographic case study methods [64, 65, 72–78]. However, to the best of our knowledge, this is the first study that uses linked interdisciplinary theoretical perspectives from innovation studies, sociology of science, and business and management to study multi-stakeholder partnerships in a BRC over 5 years. Another strength of this study is in using the principles of action research to inform real-time action and system change while also making a generalisable contribution to the knowledge base.
However, this study also has potential limitations. The ‘Partnerships’ theme has finite human and financial resources and it will not be logistically possible to explore all aspects of the questions listed in Table 1. Key data may not exist or may not be fully accessible to the research team. Ongoing access to undertake research on a multi-stakeholder research partnership, and real-time feedback of emerging findings in a way that shapes the work of that partnership, have both been shown to depend on the development of democratic relationships and mutual trust, which in turn stem from a smooth set-up phase and acknowledged early wins . Much depends on these relational preconditions, which are highly contingent and cannot be achieved purely by establishing the “right” governance structures .
It is also important to note that the study design is intentionally a single (‘n of 1’) large case study containing multiple (‘small n’) focused case studies, selected for their contrasting features. This model, favoured by leading organisational scholars as the most appropriate one for studying complex systems [38, 71], is designed to generate illuminative insights and naturalistic generalisability through the use of thick description and reflexive theorising. The study design will not generate statistically representative data, nor is it primarily intended to produce cross-case theoretical insights (as would occur, for example, in a small-n realist evaluation). In other words, we seek to answer the important and context-bound question ‘what is going on here and what can we learn from it?’, not ‘what is the effect size?’ or ‘what works for whom under different circumstances?’
The single case study design has been chosen because the NIHR Oxford BRC is a unique, dynamic and continuously evolving research system that will be influenced by future research policy developments and organisational changes. As we write this, the United Kingdom faces a changing context for scientific research, drug regulation and health services delivery as a result of its decision to leave the European Union. The unfolding of research partnerships will need to be carefully analysed with relation to what may turn out to be dramatic changes in their external context. We believe the use of the single case study for such a study is amply justified on theoretical grounds and have provided detailed philosophical explanation elsewhere [37, 80]. However, the n of 1 organisational case study is not well understood by many in the biomedical research field. There is, therefore, a risk that our findings will lack credibility in the eyes of those who value a more experimental approach and expect a ‘control group’.
In sum, this paper has described the rationale, aims, objectives and methodology for an ambitious programme of work to both support and systematically study the work of one of the largest and – currently – most successful of the NIHR’s BRCs as it enters its third 5-year funding period. The case study appears to contain many of the key ingredients for success, but there are also many unknowns, finite resources and an unstable external context. We anticipate that our methodology will, at the very least, produce a meaningful narrative in 5 years’ time of how the NIHR Oxford BRC’s fortunes unfolded and why.
The authors would like to thank the NIHR for funding, Jackie Love for her expert assistance with graphic design, and the following individuals for their contribution to the Partnerships for Health, Wealth and Innovation cross-cutting theme of the NIHR Biomedical Research Centre, Oxford. The people listed below were involved in shaping the ‘Partnerships’ theme, providing feedback on earlier drafts of this manuscript, or both:
Maxine Allen1, email@example.com
Jeroen Bergmann2, firstname.lastname@example.org
Denise Best3, email@example.com
Jacqueline Birks4, firstname.lastname@example.org
Chas Bountra5, email@example.com
Alastair Buchan2, firstname.lastname@example.org
Gary Collins6, email@example.com
Stuart Faulkner7, firstname.lastname@example.org
Gary Ford8,9, email@example.com
John Geddes10, firstname.lastname@example.org
Alastair Gray11, email@example.com
Louise Locock12, firstname.lastname@example.org
Alison Noble13, email@example.com
Christopher Pugh14,15, firstname.lastname@example.org
Mark Sheehan16, email@example.com
Joel Smith17, firstname.lastname@example.org
Adam Stoten18, email@example.com
Charles Vincent19, firstname.lastname@example.org
Glenn Wells20, email@example.com
Paul Whyte21, firstname.lastname@example.org
1Business Development, University of Oxford, Joint Research Office, Block 60, Churchill Hospital, Old Road, Oxford OX3 7LE, United Kingdom
2Institute of Biomedical Engineering, Department of Engineering Science, Old Road Campus Research Building, University of Oxford, Oxford OX3 7DQ, United Kingdom
3Medical Sciences Divisional Office, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
4Centre for Statistics in Medicine, Botnar Research Centre, University of Oxford, Windmill Road, Oxford OX3 7LD, United Kingdom
5Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom
6Centre for Statistics in Medicine, Botnar Research Centre, University of Oxford, Windmill Road, Oxford OX3 7LD, United Kingdom
7Centre for the Advancement of Sustainable Medical Innovation CASMI), Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
8Oxford Academic Heath Science Network, Oxford, United Kingdom
9Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom
10Department of Experimental Psychology, University of Oxford, 15 Parks Rd, Oxford OX1 3PH, United Kingdom
11Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, United Kingdom
12Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Primary Care Building, Woodstock Rd, Oxford OX2 6GG, United Kingdom
13Institute of Biomedical Engineering, Department of Engineering Science, Old Road Campus Research Building, University of Oxford, Oxford OX3 7DQ, United Kingdom
14Centre for Cellular and Molecular Physiology, Nuffield Department of Medicine, Oxford OX3 7BN, United Kingdom
15Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom
16Ethox Centre, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, United Kingdom
17Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford OX3 7LF, United Kingdom
18Oxford University Innovation, Buxton Court, West Way, Oxford OX2 0JB
19Risk and Safety Research Group, Department of Experimental Psychology, University of Oxford, 15 Parks Rd, Oxford OX1 3PH, United Kingdom
20Oxford Academic Health Science Centre, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom
21Business Development, University of Oxford, Joint Research Office, Block 60, Churchill Hospital, Old Road, Oxford OX3 7LE, United Kingdom
This study was funded by the National Institute for Health Research Biomedical Research Centre, Oxford, grant BRC-1215-20008 to the Oxford University Hospitals NHS Foundation Trust and the University of Oxford. The paper was drafted when TG was on a writing retreat at the Bellagio Center, Bellagio, Italy, funded by the Rockefeller Foundation. TG is supported by an NIHR Senior Investigator Award.
The paper summarises and extends a grant application on which all main authors, except PK, are named co-investigators. TG drafted the paper with the assistance of NF and PO; other authors then added specialist sections. All authors approved the final manuscript.
This study has been reviewed by, and received ethics clearance through, the University of Oxford Central University Research Ethics Committee (R51801/RE001), the Health Research Authority (IRAS ID 228049) and the Oxford University Hospitals NHS Foundation Trust Management (PID 12779).
All authors have completed the unified competing interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare (1) no financial support for the submitted work from anyone other than their employer; (2) no financial relationships with commercial entities that might have an interest in the submitted work; (3) no spouses, partners, or children with relationships with commercial entities that might have an interest in the submitted work; and (4) no non-financial interests that may be relevant to the submitted work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Trisha Greenhalgh, Email: email@example.com.
Pavel V. Ovseiko, Email: firstname.lastname@example.org.
Nick Fahy, Email: email@example.com.
Sara Shaw, Email: firstname.lastname@example.org.
Polly Kerr, Email: email@example.com.
Alexander D. Rushforth, Email: moc.liamg@htrofhsurxela.
Keith M. Channon, Email: firstname.lastname@example.org.
Vasiliki Kiparoglou, Email: email@example.com.